ArticlePain reports2016

TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study.

Prasarn Manitpisitkul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.